HAEMONETICS CORP — Director's Dealing 2013

Aug 1, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2013-07-30

Reporting Person: Kelly Michael P (President, Global Markets)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-07-30	Common Stock	D	399.0	$40.6728	Disposed	11337	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Non-Qualified Stock Option (right to buy)	$27.485	2017-07-28	Common Stock (52740)	52740	Direct
Non-Qualified Stock Option (right to buy)	$30.67	2018-10-25	Common Stock (37326)	37326	Direct
Non-Qualified Stock Option (right to buy)	$39.055	2019-10-24	Common Stock (39344)	39344	Direct
Performance Shares	$0.0	2017-12-31	Common Stock (25000)	25000	Direct

Footnotes

F1: Pursuant to a 10b5-1 Plan.

F2: Total includes Restricted Stock Awards and/or Restricted Stock Units that are subject to restrictions until vesting requirements are met. Grant was made under 2005 Long Term Incentive Compensation Plan.

F3: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.

F4: Market Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Market Stock Unit based on Haemonetics stock price during the 30 trading days prior to March 31, 2017. The number of Market Stock Units (and therefore the number of shares payable) will depend on the Companys stock price during such period. The Market Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to three times the target amount in column 5. The Market Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).